30 completed, 17 active not recruiting, 13 recruiting, 10 unknown. 81 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 81 | Completed 30, Active not recruiting 17, Recruiting 13, Unknown 10, Terminated 7, Not yet recruiting 2, Enrolling by invitation 1, Suspended 1 |
| Phase 2 | 3 | Unknown 2, Terminated 1 |
Follow exemestane: new trials by email Literature Review of exemestane trials Research Report on exemestane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Anastrozole, Biospecimen Collection, Bone Scan - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1978 | 2026-08-10 | 2026-11-06 |
| A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets - Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 5500 | 2026-03-04 | 2026-05-22 |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) LY4064809, Placebo, Ribociclib - Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Recruiting | Eli Lilly and Company | 800 | 2025-12-22 | 2026-11-04 |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. PF-07248144, Fulvestrant, Everolimus - Breast Cancer | Phase 3 | Recruiting | Pfizer | 400 | 2025-08-05 | 2026-10-19 |
| A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 240 | 2025-07-23 | 2026-10-02 |
| Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid - Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 474 | 2025-07-01 | 2025-07-11 |
| CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibitor - Breast Cancer, Adjuvant Therapy | Phase 3 | Recruiting | Fudan University | 1903 | 2025-06-15 | 2026-01-21 |
| Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer Letrozole, Anastrozole, Exemestane - Breast Cancer | Phase 3 | Not yet recruiting | Region Örebro County | 3832 | 2025-05-02 | 2025-04-20 |
| Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial Anastrozole, Letrozole, Exemestane - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8 | Phase 3 | Suspended | Alliance for Clinical Trials in Oncology | 1556 | 2025-02-19 | 2026-09-02 |
| Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) Endocrine therapy + Abemaciclib, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen - Breast Cancer, Locoregional Recurrence | Phase 3 | Recruiting | Japanese Foundation for Cancer Research | 290 | 2025-02-07 | 2025-09-29 |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) SIM0270, Everolimus (Afinitor®), Exemestane tablets - Locally Advanced or Metastatic Breast Cancer | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 482 | 2024-11-14 | 2026-08-11 |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence Elacestrant, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Active not recruiting | Stemline Therapeutics, Inc. | 4556 | 2024-09-27 | 2026-11-04 |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer Saruparib (AZD5305), Camizestrant, Abemaciclib - Advanced Breast Cancer | Phase 3 | Recruiting | AstraZeneca | 788 | 2024-08-01 | 2026-10-30 |
| Pre-Operative Window of ET to Inform RT Decisions (POWER II) Tamoxifen, Letrozole, Anastrozole, or Exemestane - Breast Cancer Female | Phase 3 | Recruiting | University of Virginia | 354 | 2024-07-19 | 2026-06-30 |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer Ribociclib, Letrozole, Ansastrozole - Early Breast Cancer | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 1466 | 2024-02-28 | 2026-11-03 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Fulvestrant, Anastrozole - Breast Cancer, Advanced Breast Cancer | Phase 3 | Active not recruiting | Olema Pharmaceuticals, Inc. | 510 | 2023-11-16 | 2026-08-13 |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Camizestrant, Tamoxifen, Anastrozole - Breast Cancer, Early Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 5511 | 2023-10-05 | 2026-08-10 |
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) Fluzoparib, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Recruiting | Fudan University | 766 | 2023-06-01 | 2024-02-08 |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Camizestrant, Tamoxifen, Anastrozole - Breast Cancer, Early Breast Cancer | Phase 3 | Recruiting | AstraZeneca | 4300 | 2023-03-31 | 2026-10-13 |
Showing 20 of 81. Sign in to see all of them.
Breast Neoplasms (70) · Breast Neoplasms, Male (4) · Neoplasm Metastasis (4) · Carcinoma, Intraductal, Noninfiltrating (2) · Neoplasms (2) · Breast Carcinoma In Situ (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Fatigue (1) · Ovarian Neoplasms (1) · Recurrence (1) · Sleep Wake Disorders (1) · Unilateral Breast Neoplasms (1)
Pfizer (6) · AstraZeneca (5) · ETOP IBCSG Partners Foundation (4) · National Cancer Institute (NCI) (4) · Novartis Pharmaceuticals (4) · Eli Lilly and Company (3) · Fudan University (3) · ARCAGY/ GINECO GROUP (2) · Alliance for Clinical Trials in Oncology (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Gruppo Italiano Mammella (GIM) (2) · Institute of Cancer Research, United Kingdom (2) · NCIC Clinical Trials Group (2) · Shandong Suncadia Medicine Co., Ltd. (2) · Stemline Therapeutics, Inc. (2)
United States (35) · Italy (24) · France (23) · Canada (22) · China (21) · Germany (20) · United Kingdom (20) · Spain (19) · Australia (18) · Argentina (16) · Belgium (16) · South Korea (16) · Brazil (15) · Hungary (14) · Puerto Rico (14)
Sabino De Placido, MD (3) · Matthew J. Ellis, MD, PhD, FRCP (2) · Paul E. Goss, MD, PhD (2) · Robert Paridaens, MD, PhD (2) · Andrea DeCensi (1) · Barbara Walley, MD, FRCPC (1) · Daniel Rea, MD (1)
PMID 21247627, PMID 24091623, PMID 24881463, PMID 29885375, PMID 35100692, PMID 41642493, PMID 41980703, PMID 23902874, PMID 25495490, PMID 26092816, PMID 27044936, PMID 28732650, PMID 28911092, PMID 29863451, PMID 31618131, PMID 36521078, PMID 36791166, PMID 40017004, PMID 40633461, PMID 40986647, PMID 41637791, PMID 10076721, PMID 11972444, PMID 12490681, PMID 12804433, PMID 12954578, PMID 14760111, PMID 15014181, PMID 15632378, PMID 15894097, PMID 16096437, PMID 16361630, PMID 16959170, PMID 17047401, PMID 17267326, PMID 17301689, PMID 17307102, PMID 17538978, PMID 18024866, PMID 18258986, PMID 18269782, PMID 18332472, PMID 18407954, PMID 18794551, PMID 18809056, PMID 19118028, PMID 19218306, PMID 19364653, PMID 19531217, PMID 20133065
2004 (3), 2023 (3), U10CA180820 (3), 2005 (2), 2008 (2), 2014 (2), 2025 (2), U10CA021115 (2), U10CA032102 (2), 2009 (1), 2016 (1), 2018 (1), U10CA180830 (1), U10CA180868 (1), U10CA180888 (1)